Oncoceutics, Inc. announced the publication of an article in the journal Cancer Research that describes the identification of several predictive markers of ONC201 response in tumor cells and promising drug combinations that may be investigated in future combinatorial clinical studies.
Large genetic and pharmacological screens were conducted with ONC201 in a panel of human cancer cells to elucidate its mechanism and identify synergistic combination therapies. Together, these findings lay out a path that maximizes the probability of clinical success for ONC201, a first-in-class molecule that has shown a high level of efficacy in both in vitro and in vivo pre-clinical models against a number of difficult-to-treat tumors with minimal side effects, including brain, breast, lymphatic, leukemic, colon and lung cancer.
“We are delighted to report the results of these highly translational preclinical studies of ONC201 that can readily be incorporated into ongoing clinical programs. While ONC201 exhibits a broad spectrum of activity as a monoagent, these studies offer molecular tools to enhance our ability to demonstrate its therapeutic potential,” said Joshua Allen, PhD, VP Development of Oncoceutics and first author of the article.
“These results provide important information that will guide how ONC201 is used in the clinic. The biomarkers and combination therapies identified in these studies can potentially be used in the future to tailor therapy for individual patients,” commented Wafik El-Deiry, MD, PhD, FACP, Professor, Co-Program Leader of Molecular Therapeutics, Deputy Cancer Center Director for Translational Research at Fox Chase Cancer Center, Scientific Founder of Oncoceutics and senior author of the article.
The link to the journal article is available here.
About Oncoceutics
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a small molecule drug with a unique mechanism of action that causes significant anti-tumor activity in a variety of types of human cancer. The Company is currently enrolling patients in clinical trials of ONC201, which began in January 2015, following acceptance by the U.S. Food and Drug Administration of the Company’s Investigational New Drug (IND) application for ONC201 in 2014. Oncoceutics and collaborative groups have received approximately $5 million in grants over the last two years from the National Institutes of Health, the Pennsylvania Department of Health, and The Musella Foundation, and the company has leveraged additional funding from academic medical research partners that support multiple Phase I/II Clinical trials.
Visit Oncoceutics or contact Rohinton Tarapore for more information
About Fox Chase Cancer Center
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet status for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase’s web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Help employers find you! Check out all the jobs and post your resume.
